| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.15 | 0.003 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.003 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.003 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.008 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.12 | 0.009 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.25 | 0.01 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |